找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: mTOR Inhibition for Cancer Therapy: Past, Present and Future; Monica Mita,Alain Mita,Eric K. Rowinsky Book 2016 Springer-Verlag France 201

[復(fù)制鏈接]
查看: 45883|回復(fù): 35
樓主
發(fā)表于 2025-3-21 19:18:56 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future
編輯Monica Mita,Alain Mita,Eric K. Rowinsky
視頻videohttp://file.papertrans.cn/643/642455/642455.mp4
概述First book on that topic.Input and perspectives by international leaders?.Preclinical and clinical data available on the subject have been integrated.A dedicated chapter on toxicity profile of mTOR in
圖書封面Titlebook: mTOR Inhibition for Cancer Therapy: Past, Present and Future;  Monica Mita,Alain Mita,Eric K. Rowinsky Book 2016 Springer-Verlag France 201
描述.This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs.? .Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation. .
出版日期Book 2016
關(guān)鍵詞Akt; cancer; mTOR; rapamycin; Molecular
版次1
doihttps://doi.org/10.1007/978-2-8178-0492-7
isbn_softcover978-2-8178-0557-3
isbn_ebook978-2-8178-0492-7
copyrightSpringer-Verlag France 2016
The information of publication is updating

書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future影響因子(影響力)




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future影響因子(影響力)學(xué)科排名




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future網(wǎng)絡(luò)公開度




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future被引頻次




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future被引頻次學(xué)科排名




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future年度引用




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future年度引用學(xué)科排名




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future讀者反饋




書目名稱mTOR Inhibition for Cancer Therapy: Past, Present and Future讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 20:49:01 | 只看該作者
板凳
發(fā)表于 2025-3-22 01:30:30 | 只看該作者
地板
發(fā)表于 2025-3-22 08:32:38 | 只看該作者
https://doi.org/10.1007/978-2-8178-0492-7Akt; cancer; mTOR; rapamycin; Molecular
5#
發(fā)表于 2025-3-22 10:50:11 | 只看該作者
6#
發(fā)表于 2025-3-22 13:50:35 | 只看該作者
Monica Mita,Alain Mita,Eric K. RowinskyFirst book on that topic.Input and perspectives by international leaders?.Preclinical and clinical data available on the subject have been integrated.A dedicated chapter on toxicity profile of mTOR in
7#
發(fā)表于 2025-3-22 19:37:43 | 只看該作者
8#
發(fā)表于 2025-3-23 01:05:21 | 只看該作者
mTOR Inhibition for Cancer Therapy: Past, Present and Future978-2-8178-0492-7
9#
發(fā)表于 2025-3-23 01:51:49 | 只看該作者
Book 2016 already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation. .
10#
發(fā)表于 2025-3-23 06:28:40 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-7 12:55
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
通河县| 綦江县| 栖霞市| 仪陇县| 佛冈县| 翁牛特旗| 全椒县| 营山县| 呼图壁县| 金阳县| 苗栗县| 铁岭市| 新邵县| 庄浪县| 花莲市| 馆陶县| 库伦旗| 明光市| 苏州市| 淳安县| 陵川县| 吉林省| 阜城县| 子长县| 吉隆县| 聂拉木县| 麻城市| 侯马市| 灵台县| 兴义市| 武鸣县| 崇义县| 镇原县| 密山市| 晋州市| 招远市| 宜宾县| 宽甸| 新河县| 建昌县| 桃源县|